Tag - CLSN

Developments

Celsion randomizes first patients in Phase 1/2 ovarian cancer study

Celsion (NASDAQ:CLSN) randomized the first two patients in the Phase 2 portion of its Phase 1/2 study evaluating GEN-1 for the treatment of advanced ovarian cancer. GEN-1 is an interleukin-12 DNA plasmid vector...

July 27, 2020

Markets

Brookline starts Celsion at buy; PT $9

Brookline Capital Markets launched coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $9 price target. The stock closed at $1.79 on July 25. Celsion is focused on clinical-stage oncology products and platform...

July 26, 2019

Tag - CLSN

Celsion randomizes first patients in Phase 1/2 ovarian cancer study

Brookline starts Celsion at buy; PT $9

General

More